News & Events


Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology Applications

Berlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.


RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay

Seattle, WA, February 27, 2020 - RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research.


RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing

SEATTLE, Dec. 19, 2019 - RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its instrument and consumables platform used in research and clinical markets. The $22M investment was led by HealthQuest Capital, with participation from 5AM Ventures and company founder, Ron Seubert.


RareCyte expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit

SEATTLE, Oct. 31, 2019 /PRNewswire/ -- RareCyte announces an addition to the RarePlex® Staining Kit product line, enabling customers to evaluate HER2 and ER expression on circulating tumor cells (CTCs) in their own laboratory. HER2 and ER are biomarkers that direct treatment recommendations for invasive breast cancer, and liquid biopsy offers a blood-based method to evaluate biomarker expression for insight into receptor status, response to treatment, and potentially therapy selection in clinical research.


RareCyte launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis

SEATTLE, Oct. 30, 2019 - RareCyte announces the launch of a new RarePlex® Staining Kit, enabling customers to evaluate prostate cancer specific expression of ARv7 on circulating tumor cells (CTC) in their own laboratory. ARv7 is the result of a splice variant of Androgen Receptor (AR), a diagnostic prostate cancer biomarker, and ARv7 is associated with resistance to second generation therapies. Liquid biopsy offers a blood-based method for researchers to evaluate CTC biomarker expression and gain insight into tumor status without an invasive biopsy.



Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial
Sponsored by: RareCyte, Inc.

This webinar describes how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly. Validation studies including analysis of accuracy and precision of CTC enumeration will be presented. As these results met the requirements of the Clinical Drug Study Team, the team at Lilly added the RareCyte platform to a global clinical trial for further evaluation in collaboration with a CRO. A short presentation on RareCyte CTC assays for enumeration, multi-biomarker analysis, and custom assay development capabilities will follow.

Jeff Fill, MBA, MT(ASCP), Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company

Arturo Ramirez, PhD, Director of Oncology, Biology R&D, RareCyte, Inc.

Wednesday, July 15, 2020 11:00 am
Eastern Daylight Time (New York, GMT-04:00)

More information and registration